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Background: Continuous veno-venous hemodiaﬁltration (CVVHDF) is a preferred
treatment modality in hemodynamically unstable acute kidney injury (AKI)
patients, because it has advantages over intermittent dialysis in terms of hemo-
dynamic stability. However, this patient group still shows a signiﬁcantly high
mortality rate. To aid in the management of these high-risk patients, we evaluated
the risk factors for mortality in CVVHDF-treated hypotensive AKI patients.
Methods: We studied 67 patients with AKI and hypotension who were treated with
CVVHDF from February 2008 to August 2010. We reviewed patient characteristics
and laboratory parameters to evaluate the risk factors for 90-day mortality.
Results: Of the 67 enrolled patients (male:female¼42:25; mean age¼69714 years),
18 (27%) survived until 90 days after the initiation of CVVHDF. There was no signiﬁcant
difference in survival rates according to the etiology of AKI [hypovolemic shock 2/10
(20%), cardiogenic shock 4/20 (20%), septic shock 12/37 (32%)]. Univariate analysis did
show signiﬁcant differences between survivors and non-survivors in the frequency of
ventilator use (44% vs. 76%, respectively; P¼0.02), APACHE II score (2977 vs. 3477,
respectively; P¼0.01), SOFA score (1174 vs. 1374, respectively; P¼0.03), blood pH
(7.370.1 vs. 7.270.1, respectively; P¼0.03), and rate of urine output o500mL for
12 hours (50% vs. 80%, respectively; P¼0.03). A multivariate Cox proportional hazards
model showed that a urine outputo500mL for 12 hours was the only signiﬁcant risk
factor for 90-day mortality following CVVHDF treatment (odds ratio¼2.1, conﬁdence
interval¼1.01–4.4, P¼0.048).
Conclusion: A urine outputo500mL for 12 hours before the initiation of CVVHDF
is an independent risk factor for 90-day mortality in hypotensive AKI patients treated
with CVVHDF.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rean Society of Nephrology. P
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ung).Introduction
Renal replacement therapy (RRT) is required in 5–6% of
critically ill patients, and acute kidney injury (AKI) requiring
dialysis, is associated with especially high mortality rates of
50–80% [1]. AKI patients requiring RRT also have a high frequency
of multiorgan failure or hemodynamic instability [2].ublished by Elsevier. This is an open access article under the CC BY-NC-
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posed as an alternative to intermittent dialysis in hemodyna-
mically unstable patients, because it is better tolerated, due to
the gradual removal of ﬂuid and uremic toxins [3–5].
Although previous studies have identiﬁed several prognos-
tic factors for mortality associated with CRRT, such as sepsis,
higher APACHE II scores, oliguric AKI, the presence of coma,
higher SOFA scores, and the need for mechanical ventilation in
critically ill patients undergoing CRRT, each study found
different results according to the indication for CRRT and the
severity of the disease [6–11]. Therefore, the prognostic factors
for patients requiring CRRT still remain somewhat obscure.
Confused classiﬁcation of patients with regard to the severity
and features of their disease, may lead to difﬁculties in identify-
ing the factors affecting the prognosis of CRRT. Nevertheless, we
attempted to assess the characteristics of patients undergoing
CRRT treatment. Therefore, this study was focused on AKI
patients with hemodynamic instability undergoing CRRT. We
evaluated the risk factors for mortality within 90 days after the
initiation of CRRT in patients with AKI and hypotension.Methods
Study population
The inclusion criteria were a clinical diagnosis of AKI and
hypotension. AKI was deﬁned by a twofold increase in serum
creatinine, a decrease in estimated glomerular ﬁltration rate (GFR)
of 450%, or a reduction in urine output o0.5 mL/kg/hour for
12 hours [12]. Hypotensionwas deﬁned by an initial mean arterial
pressure o60mmHg, or the use of vasopressors such as dopa-
mine or norepinephrine, to maintain systolic blood pressure
4100mmHg when continuous veno-venous hemodiaﬁltration
(CVVHDF) was started. A total of 108 patients were treated with
CVVHDF in the medical-surgical intensive care unit from February
2008 to August 2010. Normotensive patients and those who had
end-stage renal disease or malignancy were excluded. We identi-
ﬁed 67 patients who had AKI and hypotension at the initiation of
CVVHDF. All enrolled patients were followed for 490 days.
Treatment modality
CVVHDF was performed with the multiFiltrate (Fresenius
Medical Care, Fu¨rth, Germany) and the Ultraﬂux AV600S dialyzer
(surface area¼1.4 m2) (Fresenius Medical Care, St. Wendel,
Germany) through double-lumen catheters inserted into the
internal jugular or femoral vein. Blood ﬂow rates were main-
tained between 100 and 150mL/minute and the predilution
replacement method was used. Anticoagulation was performed
with heparin or nafamostat.
Investigated parameters
Demographic data including age, sex, diabetes mellitus,
and hypertension, and clinical parameters such as duration of
hospitalization, ventilator use, cause of hypotension, urine
output before the initiation of CVVHDF, previous surgical
intervention, and type of anticoagulation, were collected.
Laboratory parameters, including C-reactive protein, blood
urea nitrogen, serum creatinine, white blood cell count,
hemoglobin, blood pH and chest radiographic information
were also gathered at the initiation of CVVHDF.SOFA scores and APACHE II scores were employed to
evaluate the severity of disease.
Patients were assigned to two groups [RIFLE-I (injury) and
RIFLE-F (failure)] with increasing severity of RIFLE stage. We
compared demographic, clinical, and laboratory parameters
as well as mortality between these two groups.
We also compared demographic, clinical, and laboratory
parameters between the survivors and non-survivors to
identify the risk factors for mortality in hypotensive AKI
patients treated with CVVHDF.
Statistics
Data are presented as mean (standard deviation) or med-
ian and range. Between-group analyses were made using
unpaired Student t tests. Categorical variables were analyzed
using the Chi-square test or Fisher’s exact test. Cox regression
analysis was used to show the adjusted odds ratio of inves-
tigated parameters. Variables with a Po0.10 in univariate
analyses were included for multivariate analysis. Hazard
ratios with their corresponding 95% conﬁdence intervals are
reported. A Po0.05 was considered statistically signiﬁcant.Results
Baseline data and severity of illness
Basic demographic data are shown in Table 1.
A total of 67 patients were included in this study. The mean
age of the patients was 69714 years, and 42/67 (62%) were
male. The most common comorbidity was hypertension (47%),
followed by diabetes mellitus (31%). The median length of
hospital stay was 13718 days. Twenty-two out of 67 (32%)
patients had undergone surgical intervention within the previous
month. Forty-ﬁve out of 67 (66%) patients received ventilator
care and 36/67 (53%) patients showed pulmonary edema on
chest radiography before the initiation of CVVHDF. Oliguria,
deﬁned by a urine outputo500 mL within 12 hours before the
initiation of CVVHDF, occurred in 48/67 (71%) patients. Thirty-
four out of 67 (51%) patients received loop diuretics.
The most common cause of hypotension was septic shock
(37/67, 55%), followed by cardiogenic shock (20/67, 30%) and
hypovolemic shock (10/67, 15%). The mean APACHE II score
was 3277 and mean SOFA score was 1374. Mean values for
blood urea nitrogen and serum creatinine were 62734 mg/dL
and 374 mg/dL, respectively.
In univariate analysis, the rate of oliguria before the
initiation of CVVHDF was signiﬁcantly higher in the RIFLE-F
group than in the RIFLE-I group (81% vs. 58%, respectively;
P¼0.04). There was no difference in 90-day mortality
between the two groups (73% vs. 73%, respectively; P¼0.99).
Outcomes and predictors of survival
The mortality rate of the hypotensive AKI patients who
received CVVHDF was 73% (49/67).
Table 2 shows univariate comparisons of clinical charac-
teristics and laboratory ﬁndings between survivors and
nonsurvivors.
There were no signiﬁcant differences in survival rates
according to the cause of shock; septic shock (12/37, 32%),
cardiogenic shock (4/20, 20%), hypovolemic shock (2/10, 20%).
Table 2. Univariate comparisons of demographic and laboratory ﬁndings between survivors and non-survivors in hypotensive acute kidney
injury patients treated with continuous veno-venous hemodiaﬁltration (CVVHDF)
Survivors (n¼18) Non-survivors (n¼49) P
Demographic characteristics
Age (y) 65717 70713 NS
Male, n (%) 12 (67%) 30 (63%) NS
Diabetes mellitus, n (%) 7 (39%) 14 (29%) NS
Hypertension, n (%) 9 (50%) 23 (47%) NS
Clinical parameters
Duration of hospitalization, (d) 10715 15719 NS
Previous surgical intervention, n (%) 4 (22%) 18 (38%) NS
Ventilator use, n (%) 8 (44%) 37 (76%) 0.02
Pulmonary edema on chest x-ray, n (%) 6 (33%) 30 (61%) 0.06
Urine outputo500 mL for 12 h before initiation of CVVHDF, n (%) 9 (50%) 39 (80%) 0.03
Loop diuretic therapy, n (%) 8 (44%) 26 (53%) NS
Cause of shock
Septic shock, n (%) 12 (67%) 25 (51%) NS
Cardiogenic shock, n (%) 4 (22%) 16 (33%) NS
Hypovolemic shock, n (%) 2 (11%) 8 (16%) NS
Anticoagulation
Nafamostat, n (%) 3 (17%) 18 (37%) NS
Heparin, n (%) 6 (33%) 20 (41%) NS
No anticoagulation, n (%) 9 (50%) 11 (22%) NS
Severity score
APACHE II score 2977 3477 0.01
SOFA score 1174 1374 0.03
Laboratory ﬁndings on initiation of CVVHDF
BUN (mg/dL) 64731 62735 NS
Creatinine (mg/dL) 472 373 NS
C-reactive protein (mg/dL) 677 977 0.1
pH 7.370.1 7.270.1 0.03
WBC (/mm3) 14,00077,000 14,00077,000 NS
Hemoglobin (g/dL) 1173 1073 NS
Platelets (103/mm3) 1607120 120780 NS
Table 1. Baseline characteristics of hypotensive acute kidney injury patients treated with continuous veno-venous hemodiaﬁltration
(CVVHDF)
All patients (n¼67) RIFLE-I (n¼26, 39%) RIFLE-F (n¼41, 61%) P
Demographic characteristics
Age (y) 69714 66717 71712 NS
Male, n (%) 42 (62%) 16 (62%) 26 (62%) NS
Death, n (%) 49 (73%) 19 (73%) 30 (73%) NS
Diabetes mellitus, n (%) 21 (31%) 5 (19.2%) 16 (39%) NS
Hypertension, n (%) 32 (47%) 11 (42%) 21 (51%) NS
Clinical parameters
Duration of hospitalization (d) 13718 13715 14721 NS
Previous surgical intervention, n (%) 22 (32%) 13 (50%) 9 (22%) NS
Ventilator use, n (%) 45 (66%) 16 (62%) 29 (73%) NS
Pulmonary edema on chest x-ray 36 (53%) 15 (58%) 21 (51%) NS
Urine outputo500 mL for 12 h before initiation of CVVHDF, n (%) 48 (71%) 15 (58%) 33 (81%) 0.04
Loop diuretic therapy, n (%) 34 (51%) 17 (65%) 17 (41%) NS
Cause of shock NS
Septic shock, n (%) 37 (55%) 14 (54%) 25 (61%)
Cardiogenic shock, n (%) 20 (30%) 8 (31%) 10 (24%)
Hypovolemic shock, n (%) 10 (15%) 4 (15%) 6 (15%)
Anticoagulation NS
Nafamostat, n (%) 21 (31%) 10 (39%) 13 (32%)
Heparin, n (%) 26 (39%) 9 (35%) 17 (42%)
No anticoagulation, n (%) 20 (30%) 7 (27%) 11 (27%)
Severity score
APACHE II score 3277 3277 3377 NS
SOFA score 1374 1473 1274 NS
Laboratory ﬁndings on initiation of CVVHDF
BUN (mg/dL) 62734 55731 67735 NS
Serum creatinine (mg/dL) 374 371 474 0.02
C-reactive protein (mg/dL) 977 1078 877 NS
pH 7.370.1 7.370.1 7.270.1 NS
WBC (/mm3) 14,00077,000 16,00078,000 13,00077,000 NS
Hemoglobin (g/dL) 1173 1172 1073 NS
Platelets (103/mm3) 140770 130770 1507110 NS
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Table 3. Multivariate Cox proportional hazards ratio of 90-day mortality after the initiation of continuous veno-venous hemodiaﬁltration
(CVVHDF)
Odds ratio 95% Conﬁdence interval P
SOFA score 1.1 0.99–1.18 0.1
Urine outputo500 mL for 12 h before initiation of CVVHDF 2.1 1.01–4.4 0.048
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ventilation was signiﬁcantly higher for the non-survivor group
than the survivor group (76% vs. 44%, respectively; P¼0.02).
Oliguria before the initiation of CVVHDF occurred signiﬁcantly
more often in the non-survivor group than in the survivor
group (80% vs. 50%, respectively; P¼0.03). The mean APACHE
II score was signiﬁcantly higher for the non-survivor group
than for the survivor group (3477 vs. 2977, respectively;
P¼0.01), as well as the SOFA score (1374 vs. 1174, respec-
tively; P¼0.03).
Multivariate Cox proportional hazards analysis showed that a
urine outputo500 mL for 12 hours before the initiation of
CVVHDF was the only signiﬁcant risk factor for 90-day mortality
(odds ratio¼2.1, conﬁdence interval¼1.01–4.4, P¼0.048)
(Table 3). Comorbidities, cause of shock, clinical severity scores,
degree of metabolic acidosis, and type of anticoagulation were
not found to contribute to the mortality rate.Discussion
This study shows that a decreased urine output o500 mL
for 12 h before the initiation of CVVHDF, is an independent
risk factor for 90-day mortality. This result suggests that
early initiation of CVVHDF may be associated with improved
survival and that a decrease in urine output could be a
parameter used to determine the time of CVVHDF initiation
in hemodynamically unstable patients.
Several previous trials have investigated the prognostic
factors for mortality of patients undergoing CRRT; these
studies found different prognostic factors [8,10,11]. One study
showed that metabolic acidosis and earlier initiation of
CRRT were associated with the survival of patients with AKI
receiving CRRT [10]. In another study, the independent prog-
nostic factor for mortality in AKI patients treated with CRRT
was found to be the APACHE II score [7]. In the current study,
univariate analysis showed that arterial pH and APACHE II
score were signiﬁcantly different between survivors and non-
survivors. However, multivariate analysis did not show that
these factors were signiﬁcant predictors of mortality.
Bouman et al. [13] deﬁned early hemoﬁltration as treatment
started when urine output is decreased o30 mL/hour for over 6
hours and reported that early dialysis did not affect mortality.
Bae et al. [11] reported that lower mean arterial blood pressure
and lower serum bicarbonate levels measured the day after
CRRT may predict a poor prognosis. These conﬂicting results
might be caused by differences in disease severity and study
populations, because we examined prognostic factors in a group
with more severe disease and hemodynamic instability.
Our study indicates that urine output may be an important
parameter for the determination of the optimal time for CRRT.
Fluctuations in blood pressure affect renal blood ﬂow and GFR
due to renal autoregulation [14]. A marked reduction in renal
perfusion may overwhelm autoregulation and precipitate an
acute fall in GFR.After Bellomo et al. [12] ﬁrst suggested the RIFLE criteria for
the classiﬁcation of the severity of AKI and patient prognosis,
many attempts have been made to prove the usefulness of
these criteria. Studies report that when CRRT is applied at the
‘‘injury stage’’ when severity is relatively low, the mortality of
patients decreases [15–19]. In addition, a recent domestic
study also showed that the 90-day mortality rate was sig-
niﬁcantly lower in patients who received CRRT in the injury
stage of the RIFLE criteria, when compared with those in the
failure or loss stages [20]. However, the current study showed
that there was no difference in 90-day mortality between the
RIFLE-I group and the RIFLE-F group. Our results suggest that
starting treatment prior to the RIFLE-I stage may represent the
optimal timing for CRRT. Further studies using the RIFLE
criteria as a prognostic factor are needed to support this idea.
There are some limitations to our study. Firstly, it is a
retrospective, observational, single-center study, with all the
inherent limitations of such investigations. Further, our study
could not rule out the selection bias included in variable clinical
conditions and the size of the study group was relatively small.
Therefore, further prospective, multiple-center, large-group
studies will be needed to clarify the factors affecting prognosis
in hemodynamically unstable AKI patients receiving CRRT.
In conclusion, a decreased urine output o500 mL for 12 h
before the initiation of CVVHDF, is an independent prognostic
factor for mortality in AKI patients with hemodynamic instabil-
ity treated with CVVHDF. This result suggests that early initia-
tion of CRRT before a decrease in urine output is beneﬁcial.Conﬂict of interest
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